Characterization of Drug Utilization Studies (DUS) Submitted to The European Union (EU) Electronic Register of Post-Authorisation Studies (PAS)

Abstract

for infliximab-dyyb, and 35% for infliximab-abdm). Generic small-molecule drugs, however, cost 50% to 80% less than brand-name drugs. ConCluSionS: The US significantly lags in terms of market availability post-exclusivity periods in comparison to that of Europe. The small price discount of biosimilars to reference biologics could have slowed down the uptake of biosimilars in the US market.